Day: July 20, 2022

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studiesREYKJAVIK, ICELAND (July 20, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects. Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture. Xgeva® (denosumab),...

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studiesREYKJAVIK, Iceland, July 20, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects. Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of...

T4470A — Jul 20 2022 — CARIAD_STMicroelectronics_Co-Development CARIAD and STMicroelectronicsT4470A — Jul 20 2022 — CARIAD and ST Supply chain_Infographic CARIAD and Volkswagen Group aim to establish industry-leading supply chain model for automotive semiconductorsVolkswagen’s CARIAD and STMicroelectronics to co-develop chip for software-defined vehiclesNew cooperation model: CARIAD and Volkswagen Group will enter into direct relationships with semiconductor suppliers at Tier 2 and Tier 3-level for the first time. Securing Tier 3 supply: CARIAD, TSMC, and ST plan that TSMC will manufacture the system-on-chip wafers for STMicroelectronics (ST). Innovative basis: The new co-developed system-on-chip (SoC) aims to complement ST’s high-performance Stellar microcontroller family. Efficiency boost: The perfectly...

WASHINGTON, July 20, 2022 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that the firm’s Technology segment has launched a new suite of solutions within its Information Governance, Privacy & Security (“IGP&S”) practice to address the growing risks at the intersection of digital advertising and data privacy regulation. FTI Technology’s integrated suite of Advertising Technology (“AdTech”) Privacy solutions will help clients navigate emerging data privacy challenges in digital advertising and online consent management. The digital economy continues to grow at a rapid pace, driving significant spending in online advertising. The Interactive Advertising Bureau Internet Advertising Revenue Report: Full Year 2021 reported that digital advertising revenue increased by more than 35%, totaling $189 billion...

NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. In order to regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. That requirement was met on July 18, 2022. About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous,...

Midland, July 20, 2022 (GLOBE NEWSWIRE) — – Natural Gas Services Group, Inc. (NYSE:NGS) (the “Company” or “NGS”), a leading provider of gas compression technology to the energy industry, announced today, as a component of its ongoing commitment to environmental stewardship and to become a leader in energy transition efforts, a program to convert up to 100 compressor packages from combustible gas engines to electric motors over the course of the next three-to-six months. The initial conversions will focus on repurposing existing compression packages in the 200-250 horsepower range where the Company believes there is significant demand for electric units. “As we position NGS to become a leader in the energy transition, we are excited to become one of the first public compression companies to commit...